Skip to search formSkip to main contentSkip to account menu

[ LAB] SCH66336

Known as: SCH-66336, SCH66336, SCH 66336 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lonafarnib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma
We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing… 
Highly Cited
2007
Highly Cited
2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified…
PURPOSE A dose-escalation phase I and pharmacokinetic study of the farnesyltransferase inhibitor lonafarnib (SCH66336) was… 
2007
2007
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Highly Cited
2005
Highly Cited
2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
2005
2005
Farnesyltransferase inhibitor SCH‐66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration
The ras oncogenes are among those most frequently found in human cancers. Blocking Ras farnesylation is a promising strategy for… 
2003
2003
Overcoming resistance to imatinib by combining targeted agents.
Bcr-Abl, the causative molecular abnormality of CML [3][1] is known to activate numerous intracellular signaling proteins and… 
Review
2003
Review
2003
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clinical trials… 
Review
2003
Review
2003
Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Ras oncogenes (K-, H- and N-ras) are known to be involved in signal transduction pathways regulating cell growth and… 
2002
2002
Targeted therapy using novel agents in the treatment of non-small-cell lung cancer.
Patients with advanced non-small-cell lung cancer (NSCLC) have a poor prognosis and high mortality. The therapeutic improvement… 
Highly Cited
2001
Highly Cited
2001
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)